GSK Opens New Pharmaceutical Manufacturing Facilities worth $130m
GSK Launches New Pharmaceutical Production Facilities to Speed Up Production
The new GSK pharmaceutical production facility is expected to produce anemia and HIV drugs faster
GlaxoSmithKline plc. opened two new pharmaceutical manufacturing facilities in Singapore on July 5, 2019, and expanded one of the pharmaceutical production facilities on its Jurong site. GSK said in a recent press release that the pharmaceutical facility developments will enable the site to “accelerate the supply of new breakthrough medicines to patients globally”.
One of the new pharmaceutical production facilities will first develop Daprodustat, an oral treatment for anaemia associated with chronic kidney disease. It will be produced via a process called continuous manufacturing, which requires far fewer annual interventions that traditional batch manufacturing. The continuous manufacturing process is expected to reduce production time, expediting access to medicine for patients around the globe. The GSK expansion to their pharmaceutical production facility will enable faster production of active pharmaceutical ingredients used in HIV medicinal products.
“Advanced manufacturing systems are pivotal for GSK to stay at the forefront of the pharmaceutical manufacturing sector,” said Mr Lim Hock Heng, vice-president and site director at GSK’s Pharmaceuticals Supply Chain Singapore. “Further investment in digital manufacturing operations and processes will allow GSK to ensure efficient and high-quality production of our medicines.”
At the grand launch of the GSK Pharmaceutical Production Facilty, Chan Chun Sing (Trade and Industry Minister) noted that companies in the biomedical sector are now operating in an environment of precision medicine, tailored and custom-made for the individual. Singapore will distinguish itself from the competition by adhering to collaboration between companies, economic agencies and government agencies.
The kind of investment that you make in Singapore will never be recovered in a year or two. You will require a sustained presence, a predictable environment, an environment that protects your IP and an environment that enables you to try new things. In order to achieve that, we need trust and collaboration between the Government, economic agencies and GSK. It will be the same kind of trust and collaboration that we will offer to all others in the biomedical industry.
– Chan Chun Sing
Unions are a Part of the Ecosystem in the TripartiteRelationship
“If workers are left behind, then we will face in Singapore the same challenges that people face elsewhere, which is that workers will start to resist change,” he said. “If workers and unions start to resist change then there is no way that we can accomplish what we want to do together. We can build all the nice facilities, we can have all the good government and business collaborations but it will never work without the last ingredient,” added Mr Chan.
About GSK Pharmaceutical Business
GSK Pharmaceutical Production Facilities
The GSK Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. GSK R&D approach focuses on science related to the immune system, use of genetics and advanced technologies.
GlaxoSmithKline is a science-led healthcare company with a special purpose: to help people do more, feel better, live longer. We have 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies. Our Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert recommended brands in the Oral health, Pain relief, Respiratory, Skin health, Nutrition and Digestive Health categories. We have a range of Denture Care brands with Polident/Corega/Poligrip as the No.1 Denture Care brand. Visit www.gsk.com for more information.